Items tagged with Treatment
Pharmacokinetics of old and new TB drugs for children (post)
Several presentations at the 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease showed pharmacokinetic (PK) data for anti-tuberculosis (TB) drugs in children.
The REALITY trial: cotrimoxazole/isoniazid/pyridoxine tablets are bioequivalent to individual products and are acceptable to participants (post)
Cotrimoxazole/isoniazid/pyridoxine (CTX/INH/B6) scored fixed dose combination (FDC) tablets are bioequivalent to individual drugs and are acceptable, reduce pill burden and could improve adherence for adults and children, according to results from the REALITY trial presented at the 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union).
When my brother got TB, doctors said there was no hope. How could that be? (post)
Two years ago a hospital administrator confirmed that my brother Gary had tuberculosis. Then she told us the bad news.
Slight chemical change may improve TB treatments: study (post)
One small chemical change to an existing antibacterial drug results in a compound that is more effective against its target enzyme in tuberculosis, Vanderbilt researchers have discovered.
Empirical TB treatment comes up short again (post)
A South African trial has found that a strategy allowing primary care nurses to quickly provide empirical tuberculosis (TB) treatment for newly diagnosed people with advanced HIV disease at very high risk of, but without confirmed, TB did not lead to a major reduction in mortality, even though it substantially increased the percentage of people starting TB treatment. Moreover, it may have delayed initiating antiretroviral therapy (ART) for some participants when compared to those in a standard of care control arm, researchers say.
Bedaquiline plus delamanid for XDR tuberculosis (post)
We read with interest the correspondence by Caitlin Reed and colleagues, reporting a patient with a severe case of extensively drug-resistant (XDR) tuberculosis who was treated with bedaquiline and subsequently denied delamanid because of concerns over additive cardiac toxic effects.1 Here we report the case of a man with XDR tuberculosis who was treated with a regimen containing bedaquiline and delamanid in combination.
Treatment outcome of TB patients under DOTS and factors affecting outcome in Southern Ethiopia: a five-year retrospective study (post)
Abstract
Page 17 of 108 · Total posts: 0
←First 16 17 18 Last→